Fractionated stereotactic radiation therapy for orbital XXXX - a single institution experience and a short review of the literature.

@entity1 @entity227 @entity5 @entity1781 @entity158
@entity1781 ( @entity1781 ) is a rare @entity5 that generally induces a slow progressive @entity227 in affected @entity1 . Radiotherapy (RT) has currently become the first choice to treat @entity1781 . In this study our experience in @entity1781 treatment with fractionated stereotactic radiotherapy (FSRT) is reported. Five @entity1 with diagnosis of orbital @entity1781 were treated between April 2007 and December 2009 at the Radiation Oncology department of our institution. All @entity1 underwent history and physical, and ophthalmic examinations. Orbital MRI was performed before and 6 weeks after treatment; thereafter every 6 months for the first 2 years. By previous stereotactic localization of the target, RT was delivered with 28 daily fraction of 1.8 Gy by multiple non coplanar arcs dynamically conformed by a micro multileaf-collimator. At diagnosis, in all 5 @entity1 , visual acuity limitations of different degrees were found, while exophthalmos was present in 2, diplopy in 2, @entity158 in 1, and proptosis in 1. In all @entity1 pre-treatment MRI showed an orbital mass involving the optic nerve. After radiotherapy, previous symptoms improved in all @entity1 . However, after RT the MRI consistently showed a stationary status compared to the MRI before RT. At a median follow up of 26 months (range 9-37) all @entity1 had a subjective and/or objective better visual performance than before RT without any evidence of disease progression. No late side effects were recorded. Accordingly to the current literature, our experience confirms the efficacy and the safety of FSRT in @entity1 with orbital @entity1781 .
